BioArctic

BioArctic EBITDA per Employee

The EBITDA per Employee of BioArctic (BIOA B.ST) as of Oct 4, 2026 is 31.82 M SEK. In the previous year, EBITDA per Employee was -5.31 M SEK — a change of -698.71% (higher).

EBITDA per Employee

31.82 MSEK

YoY

-698.71%

Last updated:

EBITDA per Employee of BioArctic is 2026 31.82 M SEK. EBITDA per Employee of BioArctic was 2025 -5.31 M SEK. It decreases by -698.71% higher compared to the previous year.

The BioArctic EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
11.35 M SEK
Jan 1, 2019
2.85 M SEK
Jan 1, 2020
-1.73 M SEK
Jan 1, 2021
-2.94 M SEK
Jan 1, 2022
104,046.51 SEK
Jan 1, 2023
6.30 M SEK
Jan 1, 2024
-5.31 M SEK
Jan 1, 2025
31.82 M SEK
The BioArctic EBITDA per Employee history
YEAREBITDA per EmployeeYoY
31.82 MSEK-698.71%
-5.31 MSEK-184.30%
6.30 MSEK+5,958.74%
104,046.51SEK-103.54%
-2.94 MSEK+69.51%
-1.73 MSEK-160.79%
2.85 MSEK-74.86%
11.35 MSEK+2,130.94%
508,581.40SEK-71.30%
1.77 MSEK+1,094.15%
148,372.09SEK—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EBITDA per Employee of BioArctic is 31.82 M SEK in 2026.

EBITDA per Employee of BioArctic changed from -5.31 M SEK to 31.82 M SEK, representing a -698.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's BioArctic historically and in real time.

Access this data via the Eulerpool API

Workforce — BioArctic

All Key Metrics — BioArctic